Current Use of Adenovirus Vectors and Their Production Methods

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2019 Feb 2

PMID 30706395

Citations 13

Authors

Ekramy E Sayedahmed

Rashmi Kumari

Suresh K Mittal

Affiliations

Soon will be listed here.

Abstract

Various adenovirus (AdV) vector systems have proven to be lucrative options for gene delivery. They can serve as potential vaccine candidates for prevention of several common infectious diseases and hold the promise for gene therapy, especially for cancer. Several AdV vector-based therapies are currently at various stages of clinical trials worldwide, which make an immense interest of both the clinicians and researchers. Since these vectors are easy to manipulate, have broad tropism, and have the capability to yield high titers, this delivery system has a wide range of applications for different clinical settings. This chapter emphasizes on some of the current usages of AdV vectors and their production methods.

Citing Articles

Adenoviral Vectors for Gene Therapy of Hereditary Diseases.

Muravyeva A, Smirnikhina S Biology (Basel). 2025; 13(12.

PMID: 39765719 PMC: 11673936. DOI: 10.3390/biology13121052.

Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders.

Hussein N, Molina A, Sunga G, Amit M, Lei Y, Zhao X Oral Oncol. 2024; 158:106986.

PMID: 39137489 PMC: 11879773. DOI: 10.1016/j.oraloncology.2024.106986.

Nucleic acid-based drugs for patients with solid tumours.

Huayamares S, Loughrey D, Kim H, Dahlman J, Sorscher E Nat Rev Clin Oncol. 2024; 21(6):407-427.

PMID: 38589512 DOI: 10.1038/s41571-024-00883-1.

Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications.

Scarsella L, Ehrke-Schulz E, Paulussen M, Thal S, Ehrhardt A, Aydin M Viruses. 2024; 16(3).

PMID: 38543743 PMC: 10974029. DOI: 10.3390/v16030377.

Development of NP-Based Universal Vaccine for Influenza A Viruses.

Sayedahmed E, Elshafie N, Dos Santos A, Jagannath C, Sambhara S, Mittal S Vaccines (Basel). 2024; 12(2).

PMID: 38400140 PMC: 10892571. DOI: 10.3390/vaccines12020157.

References

Hardy S, Kitamura M, Dai Y, Phipps M . Construction of adenovirus vectors through Cre-lox recombination. J Virol. 1997; 71(3):1842-9. PMC: 191254. DOI: 10.1128/JVI.71.3.1842-1849.1997. View

Parks R, Chen L, Anton M, Sankar U, Rudnicki M, Graham F . A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A. 1996; 93(24):13565-70. PMC: 19345. DOI: 10.1073/pnas.93.24.13565. View

Vemula S, Amen O, Katz J, Donis R, Sambhara S, Mittal S . Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time. Virus Res. 2013; 178(2):398-403. PMC: 3919024. DOI: 10.1016/j.virusres.2013.09.013. View

ENDERS J, Bell J, DINGLE J, FRANCIS Jr T, HILLEMAN M, HUEBNER R . Adenoviruses: group name proposed for new respiratory-tract viruses. Science. 1956; 124(3212):119-20. DOI: 10.1126/science.124.3212.119. View

He T, Zhou S, DA COSTA L, Yu J, Kinzler K, Vogelstein B . A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998; 95(5):2509-14. PMC: 19394. DOI: 10.1073/pnas.95.5.2509. View

Zaiss A, Machado H, Herschman H . The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem. 2009; 108(4):778-90. PMC: 2822460. DOI: 10.1002/jcb.22328. View

Sharma A, Tandon M, Ahi Y, Bangari D, Vemulapalli R, Mittal S . Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther. 2010; 17(5):634-42. PMC: 2869393. DOI: 10.1038/gt.2010.1. View

Mittereder N, March K, Trapnell B . Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol. 1996; 70(11):7498-509. PMC: 190817. DOI: 10.1128/JVI.70.11.7498-7509.1996. View

Alba R, Bosch A, Chillon M . Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther. 2005; 12 Suppl 1:S18-27. DOI: 10.1038/sj.gt.3302612. View

10.

OHara G, Duncan C, Ewer K, Collins K, Elias S, Halstead F . Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis. 2012; 205(5):772-81. PMC: 3274376. DOI: 10.1093/infdis/jir850. View

11.

Fuchs J, Bart P, Frahm N, Morgan C, B Gilbert P, Kochar N . Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. J AIDS Clin Res. 2015; 6(5). PMC: 4648371. DOI: 10.4172/2155-6113.1000461. View

12.

Pratt W, Wang D, Nichols D, Luo M, Woraratanadharm J, Dye J . Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol. 2010; 17(4):572-81. PMC: 2849326. DOI: 10.1128/CVI.00467-09. View

13.

Van Kampen K, Shi Z, Gao P, Zhang J, Foster K, Chen D . Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2004; 23(8):1029-36. DOI: 10.1016/j.vaccine.2004.07.043. View

14.

Danthinne X, Imperiale M . Production of first generation adenovirus vectors: a review. Gene Ther. 2000; 7(20):1707-14. DOI: 10.1038/sj.gt.3301301. View

15.

Wold W, Toth K . Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013; 13(6):421-33. PMC: 4507798. DOI: 10.2174/1566523213666131125095046. View

16.

Fallaux F, Bout A, van der Velde I, van den Wollenberg D, Hehir K, Keegan J . New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther. 1998; 9(13):1909-17. DOI: 10.1089/hum.1998.9.13-1909. View

17.

Seregin S, Amalfitano A . Improving adenovirus based gene transfer: strategies to accomplish immune evasion. Viruses. 2011; 2(9):2013-2036. PMC: 3185744. DOI: 10.3390/v2092013. View

18.

Milligan I, Gibani M, Sewell R, Clutterbuck E, Campbell D, Plested E . Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA. 2016; 315(15):1610-23. DOI: 10.1001/jama.2016.4218. View

19.

Rux J, Burnett R . Large-scale purification and crystallization of adenovirus hexon. Methods Mol Med. 2007; 131:231-50. DOI: 10.1007/978-1-59745-277-9_17. View

20.

Ahi Y, Bangari D, Mittal S . Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther. 2011; 11(4):307-20. PMC: 4009923. DOI: 10.2174/156652311796150372. View